MX2023007699A - Formas solidas de un inhibidor cdk2. - Google Patents
Formas solidas de un inhibidor cdk2.Info
- Publication number
- MX2023007699A MX2023007699A MX2023007699A MX2023007699A MX2023007699A MX 2023007699 A MX2023007699 A MX 2023007699A MX 2023007699 A MX2023007699 A MX 2023007699A MX 2023007699 A MX2023007699 A MX 2023007699A MX 2023007699 A MX2023007699 A MX 2023007699A
- Authority
- MX
- Mexico
- Prior art keywords
- solid forms
- cdk2 inhibitor
- pharmaceutical compositions
- cdk2
- inhibitor
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 title 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- MTNBRBDFNSGQKB-GXTWGEPZSA-N [(1R,3S)-3-[3-[[5-(methoxymethyl)-2-methylpyrazole-3-carbonyl]amino]-1H-pyrazol-5-yl]cyclopentyl] N-propan-2-ylcarbamate Chemical compound CC(C)NC(O[C@H]1C[C@H](CC1)C1=CC(=NN1)NC(=O)C1=CC(=NN1C)COC)=O MTNBRBDFNSGQKB-GXTWGEPZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cereal-Derived Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130530P | 2020-12-24 | 2020-12-24 | |
| PCT/IB2021/062082 WO2022137106A1 (en) | 2020-12-24 | 2021-12-21 | Solid forms of a cdk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007699A true MX2023007699A (es) | 2023-07-10 |
Family
ID=79283019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007699A MX2023007699A (es) | 2020-12-24 | 2021-12-21 | Formas solidas de un inhibidor cdk2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076287A1 (enExample) |
| EP (1) | EP4267563A1 (enExample) |
| JP (2) | JP2024503235A (enExample) |
| KR (1) | KR20230122100A (enExample) |
| CN (1) | CN116723837B (enExample) |
| AU (1) | AU2021404974B2 (enExample) |
| CA (1) | CA3206153A1 (enExample) |
| MX (1) | MX2023007699A (enExample) |
| TW (1) | TWI823213B (enExample) |
| WO (1) | WO2022137106A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| CN118679150A (zh) * | 2022-01-27 | 2024-09-20 | 益方生物科技(上海)股份有限公司 | Cdk2抑制剂及其制备方法和用途 |
| WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
| WO2025191482A1 (en) | 2024-03-15 | 2025-09-18 | Pfizer Inc. | Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CA3128155C (en) * | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
-
2021
- 2021-12-21 MX MX2023007699A patent/MX2023007699A/es unknown
- 2021-12-21 WO PCT/IB2021/062082 patent/WO2022137106A1/en not_active Ceased
- 2021-12-21 AU AU2021404974A patent/AU2021404974B2/en active Active
- 2021-12-21 KR KR1020237024476A patent/KR20230122100A/ko active Pending
- 2021-12-21 CN CN202180086069.9A patent/CN116723837B/zh active Active
- 2021-12-21 EP EP21839682.8A patent/EP4267563A1/en active Pending
- 2021-12-21 CA CA3206153A patent/CA3206153A1/en active Pending
- 2021-12-21 US US18/268,959 patent/US20240076287A1/en active Pending
- 2021-12-21 JP JP2023537491A patent/JP2024503235A/ja active Pending
- 2021-12-23 TW TW110148386A patent/TWI823213B/zh active
-
2026
- 2026-04-16 JP JP2026067895A patent/JP2026123057A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230122100A (ko) | 2023-08-22 |
| TW202233606A (zh) | 2022-09-01 |
| AU2021404974A1 (en) | 2023-07-06 |
| JP2026123057A (ja) | 2026-07-29 |
| AU2021404974B2 (en) | 2024-11-28 |
| WO2022137106A1 (en) | 2022-06-30 |
| TWI823213B (zh) | 2023-11-21 |
| JP2024503235A (ja) | 2024-01-25 |
| EP4267563A1 (en) | 2023-11-01 |
| CN116723837B (zh) | 2026-05-26 |
| CN116723837A (zh) | 2023-09-08 |
| CA3206153A1 (en) | 2022-06-30 |
| AU2021404974A9 (en) | 2025-04-10 |
| US20240076287A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| ECSP23025065A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| WO2020198403A3 (en) | Compositions comprising modified circular polyribonucleotides and uses thereof | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| CL2025001913A1 (es) | Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso. | |
| MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| AR114780A1 (es) | Formulaciones estables de inmunoconjugado anti-cd79b | |
| MX2022002667A (es) | Composicion oftalmica para el tratamiento de uveitis. | |
| CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| CL2011000165A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX2022002059A (es) | Moléculas que se fijan a tdp-43 para el tratamiento de esclerosis lateral amiotrófica y trastornos relacionados. | |
| WO2020018039A3 (en) | Highly potent tacc3 inhibitor as a novel anticancer drug candidate | |
| MX2021008941A (es) | Moduladores gpr35. | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| BR112023001471A2 (pt) | Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma | |
| BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| JOP20210332A1 (ar) | عقاقير أولية لمعدلات المستقبل nmda | |
| CO2025016192A2 (es) | Moléculas y métodos de uso de estas | |
| PY1962182A (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción |